A Brief History of Agenus Inc. (AGEN)

Agenus Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies for cancer patients. The company was founded in 1994 as Antigenics Inc. by Garo H. Armen and Pramod K. Srivastava, with the goal of developing immunotherapies for cancer treatment.

Over the years, Agenus has pioneered the field of personalized cancer vaccines and has developed a number of innovative technologies to stimulate the immune system to attack cancer cells. The company has also established partnerships with various pharmaceutical companies to further its research and development efforts.

In 2015, Antigenics Inc. changed its name to Agenus Inc. to better reflect its focus on immuno-oncology. Since then, the company has continued to advance its pipeline of novel cancer immunotherapies and has made significant progress in clinical trials.

Today, Agenus Inc. is a leader in the field of immuno-oncology and is dedicated to improving the lives of cancer patients through the development of innovative therapies.

Who Owns Agenus Inc. (AGEN)

Agenus Inc. is a publicly traded company, therefore its ownership is dispersed among various shareholders. The largest shareholders of Agenus Inc. as of the latest available data are institutional investors. These institutional investors hold significant portions of the company's stock, influencing its direction and strategy.

The top institutional shareholders of Agenus Inc. include:

• Vanguard Group Inc. - Vanguard Group is one of the largest asset management companies in the world and holds a substantial stake in Agenus Inc.
• BlackRock Inc. - BlackRock is another major institutional investor with a significant ownership interest in Agenus Inc.
• State Street Corporation - State Street Corporation is a leading financial services company that also owns a notable portion of Agenus Inc.
• RA Capital Management, LLC - RA Capital Management is a healthcare-focused investment firm that is among the top shareholders of Agenus Inc.

These institutional investors play a crucial role in shaping the direction of Agenus Inc. through their ownership stakes and active participation in company decisions.

Agenus Inc. (AGEN) Mission Statement

Agenus Inc. is a biotechnology company dedicated to discovering, developing, and commercializing innovative immuno-oncology products to improve the lives of patients with cancer. Our mission is to harness the power of the immune system to combat cancer and other diseases, ultimately transforming the treatment landscape and providing hope for patients and their families.

Our commitment to research and development fuels our efforts to create novel therapies that address unmet medical needs and offer new treatment options for patients. We believe that by advancing the field of immuno-oncology, we can make a meaningful impact on patient outcomes and change the course of cancer care.

• Discover: We are dedicated to discovering new targets and pathways that can be leveraged to develop cutting-edge therapies.
• Develop: We are focused on developing our pipeline of immuno-oncology products through rigorous clinical trials and evidence-based research.
• Commercialize: We are committed to commercializing our innovative therapies to ensure they reach patients in need around the world.
• Transform: We aspire to transform the treatment landscape for cancer and other diseases by pioneering new approaches that improve patient outcomes.

How Agenus Inc. (AGEN) Works

Agenus Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of innovative immuno-oncology products. The company is dedicated to creating therapies that can help the body's immune system fight against cancer and other diseases.

Agenus utilizes a platform called Retrocyte Display technology to identify and develop potential antibody-based treatments. This technology allows them to rapidly screen thousands of antibodies to find the ones that are most effective in targeting specific antigens on cancer cells.

Once a promising antibody is identified, Agenus works on further developing the product through preclinical and clinical trials. These trials help to determine the safety and efficacy of the treatment and are crucial steps in gaining regulatory approval for commercialization.

One of the key strategies of Agenus is to collaborate with other pharmaceutical companies to advance their pipeline of products. These partnerships can provide additional resources and expertise to help bring novel therapies to market.

Overall, Agenus Inc. is committed to pushing the boundaries of immuno-oncology and developing cutting-edge treatments that have the potential to improve outcomes for patients with cancer and other serious diseases.

How Agenus Inc. (AGEN) Makes Money

Agenus Inc. is a biotechnology company that generates revenue through various sources related to the development and commercialization of immuno-oncology therapies. Below are key ways in which Agenus Inc. makes money:

• Product Sales: Agenus generates revenue through the sale of its approved products, including the Prophage Series of cancer vaccines. These products are aimed at treating various types of cancer and contribute to the company's revenue stream.
• Licensing Agreements: Agenus enters into licensing agreements with larger pharmaceutical companies for the development and commercialization of its drug candidates. These agreements often involve upfront payments, milestone payments, and royalties on sales, providing a significant source of revenue for the company.
• Collaborations and Partnerships: Agenus collaborates with other biopharmaceutical companies, academic institutions, and research organizations to advance its drug development programs. These collaborations often involve joint research efforts, funding agreements, and revenue-sharing arrangements.
• Contract Manufacturing: Agenus offers contract manufacturing services to other biopharmaceutical companies for the production of biologics, vaccines, and other pharmaceutical products. This business segment provides a steady source of revenue for the company.
• Government Grants and Funding: Agenus may receive government grants, funding, and incentives to support its research and development activities. These sources of funding help offset the costs of drug development and contribute to the company's overall revenue.